Exane Derivatives Sarepta Therapeutics, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 3 shares of SRPT stock, worth $361. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 46
93.48%
Holding current value
$361
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SRPT
# of Institutions
548Shares Held
85.5MCall Options Held
3.64MPut Options Held
1.68M-
Black Rock Inc. New York, NY10.3MShares$1.24 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.04MShares$1.09 Billion0.03% of portfolio
-
Capital International Investors Los Angeles, CA4.32MShares$520 Million0.14% of portfolio
-
State Street Corp Boston, MA4.14MShares$499 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.82MShares$459 Million0.33% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $10.5B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...